Curvilinear-gradient high-performance liquid chromatography for identification of mycobacteria

Over a 1-year period, 502 mycobacterial cultures submitted to the Microbial Diseases Laboratory were identified by high-performance liquid chromatography (HPLC) in parallel with standard biochemical methods. Identification by HPLC using a curvilinear gradient was achieved by comparing the chromatograms of the unknown cultures to chromatograms for known reference strains, together with calculation of peak height or peak area ratios, as necessary. The overall agreement between HPLC and biochemical identification was 97.2%. In addition, 7 of 12 cultures of Mycobacterium bovis were identified by HPLC as the BCG strain. Of 111 cultures biochemically identified as members of the M. avium complex (MAC), 108 were confirmed as MAC by DNA probe and 106 were confirmed by HPLC. Of the latter 106, 58 probe-positive strains were identified as M. avium, 38 were identified as M. intracellulare, and 10 were identified as Mycobacterium sp. strain "X" by HPLC. Of the remaining five nonchromogenic cultures, four had MAC-like chromatograms that did not match any in our library sufficiently to permit definitive identification. Of the latter four, two were confirmed as MAC strains by DNA probe and two were not. The last of the cultures biochemically identified as MAC (1 of 111) was a mixture of MAC and non-MAC strains. Overall, only 2 of 502 cultures yielded results by HPLC that differed from those obtained by standard biochemical methods. The HPLC result was confirmed in both cases by an independent national reference laboratory. In the 12 instances in which HPLC did not provide identification, the chromatograms were either uninterpretable or did not match available reference chromatograms. These findings show that the identification obtained by HPLC concurs well with that obtained by both the standard biochemical methods and the DNA probes. Thus, identification by HPLC provides mycobacteriology laboratories with a reproducible and specific method for accurate and timely identification of most medically important mycobacteria.

A hybrid system for diagnosing multiple disorders

This paper investigates the advantages of introducing feedback between the processes of automated medical diagnosis and automated diagnostic-knowledge acquisition. Experimental results show that a diagnostic system with such feedback is capable of an efficiency/accuracy trade-off when applied to the problem of diagnosing multiple disorders. A primary feature of this work is a new mechanism, called the "diagnostic-unit" representation, for remembering results of previous diagnoses. The diagnostic-unit representation is explicitly tailored to capture the most likely relationships between disorders and clusters of findings. Unlike typical bipartite "If-Then" representations, the diagnostic-unit representation uses a general graph representation to efficiently represent complex causal relationships between disorders and clusters of findings. In addition to the basic diagnostic-unit concept, this paper presents experience-based strategies for incrementally deriving and updating diagnostic units and the various relationships between them. Techniques for selecting diagnostic units relevant to a given problem and then combining them to generate solutions are also described.

Simultaneous analysis of flunixin, naproxen, ethacrynic acid, indomethacin, phenylbutazone, mefenamic acid and thiosalicylic acid in plasma and urine by high-performance liquid chromatography and gas chromatography-mass spectrometry

Simple and reproducible high-performance liquid chromatographic (HPLC) and gas chromatographic-mass spectrometric (GC-MS) methods have been developed for the simultaneous analysis of several acidic drugs in horse plasma and urine. Although the capillary GC-MS column provided better separation of the drugs than the reversed-phase C8 (3 microns, 75 mm) HPLC column, the total analysis time with HPLC was shorter than the total analysis time with GC-MS. The HPLC system equipped with a diode-array detector provided simultaneous screening (limit of detection 100-500 ng/ml) and confirmation (limit 1.0 micrograms/ml) of the drugs. The HPLC system equipped with fixed-wavelength ultraviolet and fluorescence detectors provided a relatively sensitive screening [limit of detection 50-150 ng/ml for ultraviolet and 10 ng/ml for fluorescence (naproxen only) detectors] of the drugs. However, the positive samples had to be confirmed by using either the diode-array detector or the GC-MS system. The GC-MS system provided simultaneous screening and confirmation of the drugs at very low concentrations (20-50 ng/ml).

Evaluation of receptor mechanism mediating fentanyl analgesia and toxicity

In the present study the antagonism of fentanyl pharmacodynamics was studied in the mouse and the receptor populations mediating the analgesic and lethal effects of fentanyl were examined. Both 1 and 8 days following implantation (s.c.) of a 15 mg naltrexone pellet there was a significant shift to the right of the fentanyl dose-response curves for analgesia and lethality. The analgesia dose-response curves were shifted significantly more (80- to 264-fold) than the lethality curves (13- to 16-fold) in the presence of naltrexone. In addition, acute naloxone (0.1 mg/kg s.c.), antagonized fentanyl analgesia more than lethality. Consequently, the relative safety ratio of fentanyl (LD50/ED50) was decreased in the presence of opioid antagonists. Pretreatment with naloxonazine (35 mg/kg s.c.) 24 h prior to testing effectively inhibited fentanyl-induced analgesia, but not fentanyl-induced lethality. However, pretreatment with beta-funaltrexamine (beta-FNA) (20 mg/kg, s.c.) 24 h prior to testing inhibited both fentanyl-induced analgesia and lethality. Implantation (s.c.) of a 75 mg morphine pellet for 72 h resulted in cross-tolerance to both fentanyl analgesia and lethality. However, the degree of the cross-tolerance was 1.8-fold for analgesia and 4.5-fold for lethality. Displacement studies of [3H]naltrexone by fentanyl in mouse brain homogenate indicated two populations of binding sites. Taken together, the pharmacodynamic studies and the binding studies suggest that fentanyl exerts its analgesic and lethal effects through different receptor populations.

Modification of morphine-induced analgesia and toxicity by pertussis toxin

The present study evaluates the effect of pertussis toxin (PTX) on morphine-induced analgesia and lethality. Mice were injected with 0.2 microgram PTX intracerebroventricularly (i.c.v.) and 0.2 micrograms PTX intrathecally (i.t.) or saline. Mice were tested for morphine-induced analgesia (tail flick) and lethality 16 days later; mice were also examined for pentobarbital-induced mortality. Morphine analgesic potency was decreased by approximately 4-fold in PTX-treated mice compared to controls. Conversely, the lethal potency of morphine was increased by 10-fold in PTX-treated mice compared to controls. PTX treatment did not alter the lethal potency of pentobarbital. Morphine-induced analgesia and lethality were dose-dependently antagonized by naloxone in both PTX and saline-treated groups. The results of this study suggest that morphine analgesia is mediated through PTX-sensitive G proteins. On the other hand, morphine-induced lethality appears to be limited by PTX-sensitive factor(s) since PTX treatment enhanced morphine's lethal potency. The increase in lethal potency of morphine may be due to unmasking of an excitatory opioid receptor mediated effect by PTX.

Myelin development in infant brain

Myelin was isolated from subcortical areas of ten human brains, with ages ranging from 24 days to 350 days-of-age; samples were subsequently analyzed for lipid composition. Eight infants were victims of Sudden Infant Death Syndrome, and two infants were accident cases. Gray and white matter samples from each brain were also dissected and analyzed. Galactolipids were only 12% of the total lipids in white matter from brains of infants that were 24 days-of-age, a time when myelination was just starting in the subcortical areas. At 175 and 350 days of age, myelination was well underway and galactolipids measured 22% of the total lipids. Total phospholipids decreased (65% to 54%) in white matter during development, with the decrease mostly in phosphatidylcholine (23% to 15%). Even though there was little white matter present at early ages, myelin could be isolated. Surprisingly, the lipid composition of myelin from the 24-day-infant brain was similar to that from adult brain. Galactolipids were 22% of the total lipids, cholesterol, 23%, and phospholipids, 52%. These results suggest that only subtle remodeling of myelin occurs in humans once myelination commences. All four major gangliosides were present in myelin during this first year of development. Interestingly, the yield of myelin from the 350-day-old infant subcortical white matter was similar to that from an adult. Thus major tracts in this area may have acquired most of the myelin by one year-after-birth. Since the control samples blend quite well into the developmental pattern obtained, it is believed there are no abnormalities in myelin lipids from SIDS infants.

Comparison of lipids and lipid metabolism in a human glioma cell line, its clone, and oligodendroglia

The human glioma cell line D-54 MG and one of its single-cell-derived clones exhibit some properties of oligodendroglia, including surface antigens, enzymatic activity, and absence of markers for astrocytes. The glioma cells were further examined for glycolipids characteristic of oligodendroglia. The glioma cells had only about 2% of the total lipids as galactolipids while oligodendroglia have 10%. Incorporation studies showed only 25% of the incorporation of galactose into galactolipids as found in oligodendroglia. Sphingomyelin and phosphatidylinositol appeared to be increased. Several phospholipids exhibited high levels of incorporation of substrates, e.g., phosphatidylcholine and phosphatidylinositol. The ganglioside patterns were much less complex for the glioma cells. Thus, the glioma cells have greatly decreased amounts of glycolipids when compared to oligodendroglia. This finding is consistent with the theory that the loss of glycolipids on the cell surface may lead to the loss of regulation of contact inhibition.

Biochemical studies of the late infantile form of metachromatic leukodystrophy

Biochemical studies from a patient with the late infantile form of metachromatic leukodystrophy are presented. Since the autopsy was performed soon after death, viable cells were isolated from brain. The purified cells had altered densities and unusual appearances. The cells when placed in culture were able to incorporate radiolabeled substrates into cerebrosides, indicating that some of the cells were of oligodendroglial origin. Myelin was isolated using several different methods, and the degree of abnormality appeared to be dependent upon the method of isolation. Nonetheless, MLD myelin, while still retaining its characteristic-morphology, had increased levels of sulfatides (two to four times that normally found). Other membrane subfractions were isolated that were not present in control tissue and that were more abnormal in composition than myelin. Finally, the glycoproteins in MLD tissue also appeared to be altered. There were losses in MLD myelin glycoproteins that bind to Concanavalin A (Con A) and additional prominent glycoproteins that bind to wheat germ agglutinin.